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Background: The left ventricular (LV) hypertrophy increases the risk of heart fail-
ure. Hypertension and infiltrative cardiomyopathies are the well-known reasons 
of LV hypertrophy. The growing interest of scientists in this issue affects hereditary 
haemochromatosis (HH), which is characterised by the excess deposition of iron 
mostly due to HFE gene mutation. The aim of our study was to investigate the 
possible influence of HH on LV parameters in patients with early-diagnosed (early 
HH) and long-lasting and long-treated (old HH) disease.
Materials and methods: Thirty nine early HH and 19 old HH patients were 
prospectively enrolled in the study; age- and sex-matched healthy volunteers 
constituted the appropriate control groups. All participants had echocardiography 
performed (including three-dimension volume and mass analysis); the iron turn-
over parameters were measured at the time of enrolment in every HH patients. 
Results: Echocardiographic parameters regarding to left atrium (LA), LV thickness, 
mass and long axis length were significantly higher, whereas LV ejection fraction 
was lower in early HH in comparison to healthy persons. In old HH patients the 
differences were similar to those mentioned before, except LV ejection fraction. 
The presence of hypertension in both HH groups did not influence echo param-
eters, as well as diabetes in old HH. The strongest correlation in all HH group was 
found between the time from HH diagnosis and LA, LV thickness and volumes 
parameters, but the correlations between iron turnover and echo parameters 
were non-existent. 
Conclusions: Hereditary haemochromatosis, not only long-lasting, but also 
early-diagnosed, could lead to exacerbation of LV wall thickness and cardiac 
hypertrophy. This effect is not simply connected with hypertension and diabetes 
that are frequent additional diseases in these patients, but with the time from 
HH diagnosis. (Folia Morphol 2019; 78, 4: 746–753)
Key words: hereditary haemochromatosis, echocardiography,  
left ventricular hypertrophy, heart siderosis, heart morphology,  
diabetes mellitus, arterial hypertension 
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INTRODUCTION
The left ventricular (LV) hypertrophy (LVH) is 
a well-known clinical and morphological parameter 
that is considered to be the important risk factor for 
heart failure [5, 8]. It occurs typically in response to 
the haemodynamic overload in some physiological 
and pathological conditions, and hypertension is the 
most important reason for LVH development [18]. The 
infiltrative cardiomyopathies are the next well-known 
reason of LVH. This is a diverse group of cardiac dis-
eases characterised by the deposition of abnormal 
substances within the heart tissue that causes the 
ventricular walls to develop either diastolic or, less 
common, systolic dysfunction. Recently the growing 
interest of scientists in this issue affects hereditary 
haemochromatosis (HH), which is characterised by 
the excess deposition of iron mostly due to HFE gene 
mutation [1, 12, 14]. Dysfunction of molecules that 
control iron homeostasis leads to excessive iron ab-
sorption in the duodenum and upper section of the 
small intestine, as well as its maldistribution. As there 
is no regulatory mechanism for iron excretion from the 
human body, iron is deposited in a variety of tissues 
and organs (liver, pancreas, skin, joints, heart) over 
the course of the disease [1, 11, 16]. Bioactive iron 
ions produce oxidative stress that destroys involved 
tissues [6, 13, 15]. Cardiomyocytes, due to intense 
iron intake, are very susceptible to this type of damage 
[17]. Symptoms of HH are nonspecific and typically 
absent in the early stages, therefore a high degree 
of clinical suspicion is key to making the diagnosis. 
Echocardiography, especially with the use of novel 
three-dimension (3D) techniques, is one of the most 
important tools for revealing cardiac abnormalities; 
LVH is one of the most noticeable alterations which 
can be detected by echocardiography and is very com-
mon complication of HH. Therefore, the aim of our 
study was to investigate the possible influence of HH 
on LV parameters in different groups of HH patients: 
with early-diagnosed disease and with long-lasting 
and long-treated pathology. 
MATERIALS AND METHODS
Study population
From November 2014 to November 2018, we 
prospectively enrolled the patients with newly diag-
nosed HH (i.e. within 3 months of the initial clinical 
diagnosis, before receiving HH-specific treatment) 
[early HH] and the patients with HH treated at least 
5 years [old HH]. HH was initially diagnosed in specialist 
clinic based on clinical characteristics, abnormal iron 
turnover parameters and the presence of HFE gene 
mutations [4]. Healthy age- and sex-matched volun-
teers constituted two control groups: 26 to early HH 
and 24 to old HH patients. All participants underwent 
classic echocardiography imaging. The protocol of the 
study was approved by the Local Ethics Committee 
at the Medical University of Gdansk, and written in-
formed consent was obtained from all participants. 
The exclusion criteria were as follows: age < 18 years; 
history of any cardiological diagnosis (apart from the 
hypertension). In all HH patients, the levels of iron, 
serum ferritin, transferrin saturation, haemoglobin, 
glucose and transaminases level were measured at 
the time of enrolment.  
Echocardiography
Echocardiography was performed in every person 
enrolled into the study. The patients were examined in 
the left lateral decubitus position using a GE VIVID E9 
ultrasound system (GE Ultrasound, Horten, Norway) 
equipped with phased-array transducer (M5S). During 
the same echocardiographic examination 3D datasets 
were acquired in apical view using a commercially 
available matrix-array 3D transducer (4V). 
Standard echocardiographic parameters were ob-
tained according to the principles described in rec-
ommendations [9]. Data acquisitions were obtained 
from parasternal long- and short-axis views and the 
three standard apical views. For each view, three 
consecutive cardiac cycles were recorded during quiet 
respiration. Grayscale recordings were optimised for 
LV evaluation at a frame rate of 50–80 frames/s and 
only persons with these parameters were includ-
ed into the further analyses. All echocardiograms 
were stored digitally and further offline analysis was 
performed using commercial workstation EchoPAC 
(v201, GE Healthcare Horten, Norway).
Analysis of 2D parameters. Left atrium (LA) di-
ameters (LADs), indexed LA area (LAA index) and 
indexed LA volume (LAV index), LV end-diastolic di-
ameters (LVEDD), LV end-systolic diameter (LVESD), 
intraventricular septal (IVS) and posterior wall (PW) 
thickness were measured in parasternal view. The rela-
tive wall thickness (RWT) was calculated as the sum of 
anteroseptal and posterior wall thickness divided by 
the LV end-diastolic dimension. LV diastolic longitudi-
nal length was measured as the distance between the 
mitral annulus and the apex in end-diastole averaged 
from the 4-, 2- and 3-chamber apical views. 
748
Folia Morphol., 2019, Vol. 78, No. 4
Analysis of 3D parameters. After manual align-
ment of the three apical views and the short-axis 
view, points were placed in the mitral annular plane 
and at the apex, in end-diastole and end-systole. En-
docardial and epicardial border were automatically 
detected by the software, but manually corrected, if 
necessary. End-diastolic (LVEDV), end-systolic (LVESV) 
volumes, 3D LV ejection fraction (LVEF) and LV mass 
(LVM) were measured (Fig. 1).  
Statistical analysis
Continuous data are presented as the median 
(25th–75th percentiles), while categorical data are ex-
pressed as proportions. We performed the Shapiro- 
-Wilk test to determine whether our data were nor-
mally distributed. The majority of the analysed pa-
rameters did not have normal data distributions, 
even after logarithmic data transformation; thus, 
we selected appropriate statistical analysis methods 
based on non-parametric tests. Comparisons between 
groups were performed with the Mann-Whitney U 
test for continuous variables and Pearson’s chi-square 
test for categorical variables, when appropriate. The 
correlations between laboratory parameters and 
echo parameters were evaluated using Spearman’s 
correlation coefficient. P-values less than 0.05 were 
considered significant. The statistical analysis was 
conducted with STATISTICA 9.0 (StatSoft, Tulsa OK, 
USA) and R 2.15.2.
RESULTS
Thirty nine patients constituted the early HH group 
and 19 patients the old HH group, age- and sex- 
-matched healthy volunteers constituted the appro-
priate control groups (due to the fact that the old 
HH patients were older than early HH patients, there 
were two respective control groups in our study). The 
genetic characteristics of the early HH patients were 
as follows: 28 patients had the C282Y/C282Y geno-
type, 7 — C282Y/H63D genotype, 3 — H63D/H63D 
genotype, and 1 — C282Y/wt genotype, whereas the 
old HH patients were C282Y/C282Y, except 2 patients 
— C282Y/H63D. 
Table 1 shows biochemical results of the patients 
at the time of enrolment. Early HH had significantly 
higher ferritin level, whereas the glycaemia level was 
higher in old HH group. 
In comparison between early HH group and the 
healthy persons there were a number of differences 
regarding to: LA parameters (LADs and LAV index), LV 
thickness (IVS, PW and RWT) and mass (LVM index), as 
well as to LV long axis length, which appeared to be 
significantly higher in early HH patients. Figures 2A–C 
demonstrate the example of 2D echo views in early HH 
patients, whereas Figures 3A–C — the 2D echogram 
of the healthy person. 3D echocardiography showed 
bigger LVESV and lower LVEF in early HH patients 
(Table 2). It should be noted that all mentioned echo 
parameters were within the normal range.
Table 1. HH patients’ laboratory characteristics at enrolment
Early HH (n = 39) Old HH  (n = 19) P
Iron [µg/dL] 170 (148–215) 159 (130.5–214) 0.233
Ferritin [ng/mL] 421.5 (271–860) 192 (82–223) < 0.001
TSAT [%] 79 (60.5–91.8) 71 (65.8–81.5) 0.228
Haemoglobin [mg/dL] 15.1 (14–16) 15.1 (14.2–16) 0.474
Glycaemia [mg%] 94 (87–98) 103 (97–104) < 0.009
ASPAT [U/L] 24 (18–38) 24 (20.5–37) 0.433
ALAT [U/L] 35 (24–64) 26 (21–44) 0.209
Data are presented as the median (25th–75th percentile); TSAT — transferrin saturation; ASPAT—aspartate transaminase; ALAT — alanine transaminase
Figure 1. The example of three-dimensional, full-volume echo view  
for volume, mass and ejection fraction assessment; LA — left atrium;  
LV — left ventricle; RA — right atrium; RV — right ventricle.
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In old HH patients the differences were very similar 
to those mentioned before; there were differences 
in the LA parameters (LADs, LAA index, LAV index), 
LV thickness (IVS, PW, RWT, LVM index) and LV long 
Figure 3. A. The example of parasternal long-axis view in healthy person (IVS 9 mm, PW 9 mm). Arrows point the locations where the meas-
ures were taken; B. The example of parasternal short-axis view in healthy person (IVS 10 mm). Arrow points the location where the measure 
was taken; C. The example apical 4-chamber view in healthy person. Arrow points the location where the measure was taken; RA — right 
atrium; RV — right ventricle; LA — left atrium; LV — left ventricle; IVS — intraventricular septum; PW — posterior wall.
Figure 2. A. The example of parasternal long-axis view in early HH patient (IVS 12 mm, PW 12 mm). Arrows point the locations where the 
measures were taken; B. The example of parasternal short-axis view in early HH patient (IVS 12 mm). Arrow points the location where the 
measure was taken; C. The example apical 4-chamber view in early HH patient. Arrow points the location where the measure was taken;  
IVS — intraventricular septum; LA — left atrium; LV — left ventricle; RA — right atrium; RV — right ventricle; PW — posterior wall.
A B C
A B C
Table 2. Comparison of echocardiographic parameters between early HH and healthy groups
Healthy volunteers (n = 26) Early HH (n = 39) P
Age [years] 44 (35–53) 38 (31–53) 0.199
LADs [mm] 37 (34–39) 42 (36–45) < 0.003
LAA index [cm2/BSA] 9.0 (8.2–9.85) 9.1 (7.8–10.1) 0.418
LAV index [mL/BSA] 21 (18–24) 27 (23–34) < 0.001
IVS [mm] 9 (7–9) 10 (8–11) < 0.005
PW [mm] 8 (7–9) 9 (7–10) < 0.043
RWT 0.37 (0.33–0.41) 0.42 (0.38–0.46) < 0.001
LVEDD [mm] 44 (42–47) 45 (43–48) 0.111
LVESD [mm] 28 (26–29) 28 (25–29) 0.487
LVM index [g/BSA] 65 (54–71) 67 (56–92) < 0.045
LV long axis length [mm] 74 (69–79) 78 (74–81) < 0.033
LVEDV [mL] 105 (89–124) 118 (97–133) 0.089
LVESV [mL] 38 (33–46) 50 (39–56) < 0.005
LVEF [%] 63 (61–65) 60 (54–61) < 0.001
Data are presented as the median (25th–75th percentile); BSA — body surface area; LV — left ventricular; LADs — left atrial diameters; LAA index — left atrium area/BSA; LAV index — 
left atrium volume/BSA; IVS — intraventricular septum; PW — posterior wall; RWT — relative wall thickness; LVEDD — LV end-diastolic diameter; LVESD — LV end-systolic diameter; 
LVM index — LV mass/BSA; LVEDV — LV end-diastolic volume; LVESV — LV end-systolic volume; LVEF — LV ejection fraction
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axis length, but the differences in LVEDV, LVESV and 
LVEF were not statistically significant (Table 3).
When conducting the separate analysis for early 
HH and old HH with and without arterial hypertension 
we did not confirm the differences in LV thickness 
parameters (IVS, PW, RWT); LVM index was similar in 
compared patients as well (Table 4).
Among 19 old HH patients, 6 had diabetes. Compar-
ing the echocardiographic parameters between those 
with and without diabetes, we did not confirm the dif-
ferences in LV thickness parameters (IVS, PW, RWT); LVM 
index was similar in compared patients as well (Table 5). 
Among early HH patients, only 2 had diabetes; therefore, 
the statistical analysis was not appropriate for this group.
Table 3. Comparison of echocardiographic parameters between old HH and healthy groups 
Healthy volunteers (n = 24) Old HH (n = 19) P
Age [years] 49 (43–62) 53 (48–65) 0.183
LADs [mm] 38 (34–39) 42 (38–43) < 0.004
LAA index [cm2/BSA] 9.2 (8.0–9.9) 10.5 (8.2–12.0) 0.082
LAV index [mL/BSA] 22 (19–28) 35 (32–39) < 0.001
IVS [mm] 9 (7–10) 12 (10–12) < 0.001
PW [mm] 8 (7–10) 11 (9–12) < 0.001
RWT 0.38 (0.34–0.43) 0.44 (0.39–0.49) < 0.019
LVEDD [mm] 45 (42–47) 46 (45–49) 0.062
LVESD [mm] 28 (26–30) 29 (25–34) 0.215
LVM index [g/BSA] 68 (55–73) 93 (77–102) < 0.001
LV long axis length [mm] 72 (66–77) 81 (73–82) < 0.004
LVEDV [mL] 96 (86–120) 93 (79–111) 0.225
LVESV [mL] 36 (33–43) 37 (28–45) 0.476
LVEF [%] 63 (61–65) 61 (55–65) 0.093
Data are presented as the median (25th–75th percentile); BSA — body surface area; LV — left ventricular; LADs — left atrial diameters; LAA index — left atrium area/BSA; LAV index — 
left atrium volume/BSA; IVS — intraventricular septum; PW — posterior wall; RWT — relative wall thickness; LVEDD — LV end-diastolic diameter; LVESD — LV end-systolic diameter; 
LVM index — LV mass/BSA; LVEDV — LV end-diastolic volume; LVESV — LV end-systolic volume; LVEF — LV ejection fraction
Table 4. Comparison of echocardiographic parameters between HH patients with and without arterial hypertension
Early HH without  
hypertension (n = 29)
Early HH with  
hypertension (n = 10)
P Old HH without  
hypertension (n = 7)
Old HH with  
hypertension (n = 12)
P
Age [years] 33 (30–44) 55 (53–61) < 0.001 50 (42–55) 59 (53–65) 0.102
LADs [mm] 37 (34–42) 44 (42–45) < 0.008 35 (34–42) 43 (42–45) < 0.018
LAA index [cm2/BSA] 8.7 (7.8–9.8) 9.6 (8.1–10.5) 0.145 9.2 (8.1–10.7) 11.3 (9.1–12.7) 0.123
LAV index [mL/BSA] 24 (22–30) 34 (32–38) 0.021 32 (27–36) 35 (34–42) 0.080
IVS [mm] 10 (8–11) 11 (8–12) 0.231 12 (10–13) 12 (10–12) 0.481
PW [mm] 9 (7–10) 10 (8–11) 0.151 10 (9–11) 11 (9–12) 0.322
RWT 0.42 (0.38–0.45) 0.42 (0.37–0.49) 0.417 0.4 (0.38–0.45) 0.47 (0.4–0.51) 0.170
LVEDD [mm] 46 (43–48) 45 (42–49) 0.436 47 (46–50) 45 (43–48) 0.146
LVESD [mm] 28 (26–30) 27 (25–29) 0.214 28 (25–32) 29 (26–34) 0.428
LVM index [g/BSA] 66 (56–80) 90 (56–100) 0.148 95 (93–103) 84 (72–100) 0.149
LV long axis [mm] 78 (74–83) 77 (74–81) 0.232 82 (82–85) 77 (72–81) < 0.046
LVEDV [mL] 118 (97–133) 123 (104–134) 0.458 110 (97–113) 84 (76–99) 0.192
LVESV [ml] 51 (39–56) 50 (42–56) 0.442 39 (28–52) 37 (30–41) 0.435
LVEF [%] 57 (54–62) 60 (59–60.3) 0.299 62 (53–67) 60 (57–64) 0.414
Data are presented as the median (25th–75th percentile); BSA — body surface area; LV — left ventricular; LADs — left atrial diameters; LAA index — left atrium area/BSA; LAV index — 
left atrium volume/BSA; IVS — intraventricular septum; PW — posterior wall; RWT — relative wall thickness; LVEDD — LV end-diastolic diameter; LVESD — LV end-systolic diameter; 
LVM index — LV mass/BSA; LVEDV — LV end-diastolic volume; LVESV — LV end-systolic volume; LVEF — LV ejection fraction
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The strongest correlations in all HH group were 
found between the time from HH diagnosis and LA 
parameters (LADs, LAA index, LAV index), LV thickness 
parameters (IVS, PW, LVM index) and LV volumes 
(LVEDV and LVESV), whereas there were no corre-
lations between iron turnover and echo parameters 
(Table 6).  
DISCUSSION
The most important finding of our study is the 
observation that in patients with HH the parame-
ters regarding to LV wall thickness were significantly 
worse than in age-matched healthy persons. Those 
differences were independent of hypertension and 
diabetes, but correlated with the time from initial HH 
Table 5. Comparison of echocardiographic parameters between old HH patients with and without diabetes mellitus 
Old HH without diabetes (n = 13*) Old HH with diabetes (n = 6*) P
Age [years] 51 (44–57) 64.5 (58–66.5) < 0.035
LADs [mm] 42 (35–43) 44 (42–45) < 0.030
LAA index [cm2/BSA] 10.5 (8.3–11.5) 11.5 (8.6–13.5)  0.192
LAV index [ml/BSA] 35 (31–38) 36 (34–43) 0.174
IVS [mm] 11 (10–12) 12 (11–14) 0.100
PW [mm] 10 (9–11) 12 (11–12) 0.090
RWT 0.42 (0.36–0.47) 0.49 (0.45–0.52) 0.061
LVEDD [mm] 47 (45–48) 46 (42–48) 0.318
LVESD [mm] 29 (25–31) 31 (25–34) 0.444
LVM index [g/BSA] 93 (75–96) 95 (85–117) 0.227
LV long axis length [mm] 82 (74–82) 79 (73–84) 0.462
LVEDV [mL] 101 (88–112) 80 (75–83) 0.128
LVESV [mL] 40 (34–49) 29 (26–37) 0.167
LVEF [%] 60 (54–62) 65 (58–66) 0.182 
Data are presented as the median (25th–75th percentile); BSA — body surface area; LV — left ventricular; LADs — left atrial diameters; LAA index — left atrium area/BSA; LAV index — 
left atrium volume/BSA; IVS — intraventricular septum; PW — posterior wall; RWT — relative wall thickness; LVEDD — LV end-diastolic diameter; LVESD — LV end-systolic diameter; 
LVM index — LV mass/BSA; LVEDV — LV end-diastolic volume; LVESV — LV end-systolic volume; LVEF — LV ejection fraction
Table 6. Correlations between iron turnover and echo parameters in all HH patients
Iron Ferritin Transferrin saturation Time from diagnosis
r p r p r p r p
LADs [mm] 0.110 0.414 0.058 0.669 0.161 0.239 0.189 0.160
LAA index [cm2/BSA] –0.005 0.974 –0.138 0.323 –0.134 0.345 0.400 < 0.003
LAV index [mL/BSA] –0.017 0.903 –0.193 0.167 –0.052 0.714 0.395 < 0.003
IVS [mm] –0.077 0.569 0.067 0.626 –0.116 0.398 0.522 < 0.001
PW [mm] 0.020 0.880 –0.035 0.795 –0.118 0.390 0.496 < 0.001
RWT 0.027 0.843 0.035 0.800 –0.048 0.727 0.259 0.051
LVEDD [mm] 0.044 0.744 0.201 0.138 0.103 0.453 0.195 0.125
LVESD [mm] –0.036 0.790 –0.081 0.553 –0.044 0.752 0.211 0.115
LVM index [g/BSA] –0.031 0.818 0.075 0.581 –0.037 0.789 0.530 < 0.001
LV long axis [mm] 0.101 0.467 0.201 0.149 –0.213 0.129 0.055 0.695
LVEDV [mL] 0.152 0.659 0.117 0.424 –0.144 0.330 –0.337 < 0.018
LVESV [mL] 0.065 0.659 0.117 0.424 –0.144 0.330 –0.337 < 0.018
LVEF [%] 0.068 0.640 0.008 0.957 –0.041 0.780 0.219 0.130
BSA — body surface area; LV — left ventricular; LADs — left atrial diameters; LAA index — left atrium area/BSA; LAV index — left atrium volume/BSA; IVS — intraventricular septum; 
PW — posterior wall; RWT — relative wall thickness; LVEDD — LV end-diastolic diameter; LVESD — LV end-systolic diameter; LVM index — LV mass/BSA; LVEDV — LV end-diastolic 
volume; LVESV — LV end-systolic volume; LVEF — LV ejection fraction
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diagnosis. The additional novelty of our study can be 
found in the demonstration that not only long-lasting 
HH leads to LVH, but even early-diagnosed HH is charac-
terised by higher LV wall thickness parameters in com-
parison to age- and sex-matched healthy volunteers. It 
is worth to note, that early HH subgroup of patients 
was established in short time (within 3 months) after 
initial diagnosis, before specific HH treatment. However, 
despite the lack of any cardiological symptoms and the 
absence of cardiological history, they presented worse 
LV thickness parameters. Myocardial iron loading of 
the heart is well known as a possible complication in 
late stages of HH in terms of both diastolic and systolic 
function [6], but we revealed some differences in heart 
morphology even in early-diagnosed, not treated HH, 
where LV thickness parameters were lower than in the 
old HH patients, but were prominent and significantly 
worse than in control group.
When evaluating the overall results of this study, it 
should be noted, that echocardiographic assessment 
of HH patients revealed some other differences in 
comparison with healthy volunteers. Besides augmen-
tation of rudimentary parameters (IVS, PW, RWT) we 
detected increased LA parameters, which is known as 
a typical consequence of LVH and diastolic dysfunc-
tion. In addition, LV long axis length, volume and mass 
were significantly worse in HH patients in comparison 
with controls; these differences have been noted in 
both HH groups. All of this undoubtedly suggests that 
we may deal with haemochromatosis-induced cardio-
myopathy rather, than with simple LV thickening. This 
statement, however, needs to be confirmed in further 
studies with larger groups of HH patients and possible 
follow-up period. According to methodology of our 
study, it should be underlined, that LV volume and 
mass were quantified with the use of 3D echocardio-
graphy — the technique, which is considered to be 
comparable with magnetic resonance in relation to 
abovementioned parameters [2, 7].
Finally, it is important to refer to common HH 
comorbidities: hypertension and diabetes. LVH is an 
important marker of hypertension [10, 19, 20] and 
diabetes-mediated organ damage [3]. That is why we 
ruled out the possible impact of these pathologies on 
LV thickness, demonstrating the lack of significant 
differences (Tables 4, 5). 
We are well aware of potential limitations of our 
study. This was a small, single-centre study, and there-
fore its results need to be confirmed in a larger group 
of patients. 
CONCLUSIONS
Hereditary haemochromatosis, not only long- 
-lasting, but also early-diagnosed, could lead to 
exacerbation of LV wall thickness and cardiac hyper-
trophy. This effect is not simply connected with hy-
pertension and diabetes that are frequent additional 
diseases in these patients, but with the time from 
HH diagnosis. 
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